Wells Fargo upgrades Pulmonx to Overweight, raises price target to $15

As previously reported, Wells Fargo analyst Larry Biegelsen upgraded Pulmonx to Overweight from Equal Weight with a price target of $15, up from $10. Gaining traction post-COVID, the firm believes both pipeline and valuation look "attractive."